MedTrace Logo

Atorvastatin Effect on Contrast Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention

NCT04375787 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-02-16

No results posted yet for this study

Summary

Investigate of the potential benefit of acute pretreatment with high dose atorvastatin (80 mg) in reduction of the incidence of CIN in diabetic patients indicated for elective coronary intervention.

Conditions

  • Coronary Disease

Interventions

DRUG

Atorvastatin

Patients received 80 mg atorvastatin before elective coronary angiography

Sponsors & Collaborators

  • Mohamed Abdelfatah

    lead OTHER

Principal Investigators

  • Ayman Ibrahem, MD · Assiut University

  • Ahmed Abdel-Galeel, MD · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-15
Primary Completion
2020-06-02
Completion
2020-06-02
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04375787 on ClinicalTrials.gov